This trial is testing whether a less radical surgery is just as effective as a more radical surgery for melanoma.
- Cutaneous Melanoma Stage II
1 Primary · 10 Secondary · Reporting Duration: Within 1 year from randomisation
2 Treatment Groups
Arm B (Wide Local Excision = 2cm Margin)
1 of 2
Arm A (Wide Local Excision = 1cm Margin)
1 of 2
2998 Total Participants · 2 Treatment Groups
Primary Treatment: Wide Local Excision = 1cm Margin · No Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 9 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How large is the test group for this experiment?
"The information available on clinicaltrials.gov does show that this trial is actively recruiting patients as of right now. This trial was initially posted on December 17th, 2019 and the most recent update was October 24th, 2020. They are looking for 2,998 patients in total from 48 different sites." - Anonymous Online Contributor
Is the FDA's decision to approve Wide Local Excision with a 1cm Margin supported by scientific research?
"Power has given Wide Local Excision = 1cm Margin a safety score of 3. This is based off the fact that it is a phase 3 trial, and thus there is both evidence of efficacy as well as multiple rounds of data supporting safety." - Anonymous Online Contributor
In how many different locations is this trial being conducted?
"In total, there are 48 patients enrolled in this trial at various locations including VCU Massey Cancer Center in Richmond, Marshfield Medical Center - Marshfield in Marshfield, and University of Kansas Hospital - Indian Creek Campus in Overland Park." - Anonymous Online Contributor
Is this research available to participants at the present time?
"Yes, the trial is recruiting patients as of now. The date when this study was first posted on clinicaltrials.gov was December 17th, 2019 and the most recent update to the trial information occurred on October 24th, 2020." - Anonymous Online Contributor